To include your compound in the COVID-19 Resource Center, submit it here.

Prothena discontinues development of psoriasis/psoriatic arthritis candidate

Prothena Corp. plc (NASDAQ:PRTA) said Phase Ib data for PRX003 do not support moving the psoriasis/psoriatic arthritis candidate into mid-stage development.

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE